$2.2 Billion Wound Care Biologics Market - Global Forecast to 2023
DUBLIN, June 7, 2018 /PRNewswire/ --
The "Wound Care Biologics Market by Product (Biological Skin Substitutes (Biosynthetic Products), Topical Agents), Wound Type (Diabetic Foot Ulcer, Pressure Ulcers, Surgical & Traumatic Wound), End User (Hospitals, Burn Centers) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The global wound care biologics market is expected to reach USD 2.26 Billion by 2023 from USD 1.42 Billion in 2018, at a CAGR of 9.8%.
Market growth is mainly driven by factors such as the increasing incidence of diabetic foot ulcers, increasing geriatric population, and increasing burn injuries globally. On the other hand, the high cost of wound care biologics and the higher rejection rate associated with skin grafts & substitutes will restrain the growth of this market.
The global wound care biologics market is segmented on the basis of product, wound type, end user, and region. By product, the wound care biologics market segmented into biological skin substitutes and topical agents. The biological skin substitutes segment is estimated to account for the largest share of the market in 2018. The rising incidence of hard-to-heal wounds and their growing adoption (due to their high efficacy) are driving the growth of this product segment. The biological skin substitutes segment is further categorized into human donor tissue-derived products, acellular animal-derived products, and biosynthetic products.
On the basis of wound type, the wound care biologics market is segmented into ulcers, surgical & traumatic wounds, and burns. In 2018, the ulcers segment is expected to account for the largest share of the wound care biologics market. Market growth can primarily be attributed to the widespread adoption of wound care biologics for the treatment of ulcers and burn injuries in developed countries and the high incidence rate of diabetic foot ulcers.
On the basis of end user, the wound care biologics market is segmented into hospitals, ASCs, and burn centers & wound clinics. In 2017, the hospitals segment accounted for the largest share of the market. Hospitals are the largest end users of wound care biologics, as most of the wound care treatment using biologics are conducted in hospital settings.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Wound Care Biologics Market Overview
4.2 Geographic Analysis: Wound Care Biologics Market, By Product (2018)
4.3 Geographic Snapshot of the Wound Care Biologics Market
4.4 Wound Care Biologics Market, By Wound Type
5 Market Overview
5.1 Introduction
5.2 Reimbursement Scenario for Skin Substitutes in the US
5.2.1 General Criteria Covered
5.2.2 Apligraf, Theraskin, and Epifix
5.2.3 Dermagraft
5.2.4 Integra
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rising Incidences of Burn Injuries
5.3.1.2 Rapid Growth in the Geriatric Population
5.3.1.3 Growing Incidence of Ulcers and Target Conditions
5.3.1.4 Innovation in Wound Care Biologics
5.3.1.5 Awareness Programs for Wound Care Treatment and Management
5.3.2 Market Restraints
5.3.2.1 High Cost of Wound Treatment and Wound Care Biologics
5.3.2.2 Risk of Skin Substitute Failure
5.3.3 Market Opportunities
5.3.3.1 Increasing Research on Advanced Wound Treatments
5.3.3.2 3d Skin Printing
6 Wound Care Biologics Market, By Product
6.1 Introduction
6.2 Biological Skin Substitutes
6.2.1 Human Donor Tissue-Derived Products
6.2.2 Acellular Animal-Derived Products
6.2.3 Biosynthetic Products
6.3 Topical Agents
7 Wound Care Biologics Market, By Wound Type
7.1 Introduction
7.2 Ulcers
7.2.1 Diabetic Foot Ulcers
7.2.2 Venous Ulcers
7.2.3 Pressure Ulcers
7.2.4 Other Ulcers
7.3 Surgical & Traumatic Wounds
7.4 Burns
8 Wound Care Biologics Market, By End User
8.1 Introduction
8.2 Hospitals
8.3 Ambulatory Surgical Centers
8.4 Burn Centers and Wound Clinics
9 Wound Care Biologics Market, By Region
10 Competitive Landscape
10.1 Overview
10.2 Market Share Ranking, 2017
10.3 Top Ranking Companies in the Wound Care Biologics Market
10.4 Wound Care Biologics Market Share Analysis in the Us, 2017
10.5 Competitive Scenario
10.5.1 Product Launches and Approvals
10.5.2 Agreements
10.5.3 Acquisitions
10.5.4 Expansions
10.5.5 Other Developments
11 Company Profiles
11.1 Smith & Nephew
11.2 Mlnlycke Health Care AB (Investor AB)
11.3 Integra Lifesciences
11.4 Wright Medical
11.5 Mimedx Group
11.6 Vericel
11.7 Anika Therapeutics
11.8 Osiris Therapeutics
11.9 Organogenesis
11.10 Kerecis
11.11 Solsys Medical
11.12 Acell
11.13 Marine Polymer Technologies
For more information about this report visit https://www.researchandmarkets.com/research/snm85g/2_2_billion?w=5
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article